Can a new biologic tame ulcerative colitis?
NCT ID NCT07747467
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This early trial is testing an experimental biologic drug called aletekitug in adults with moderate to severe ulcerative colitis. The main goal is to see if the drug is safe and tolerable when given repeatedly. Researchers will monitor side effects and changes in lab tests, vital signs, and heart readings. The study uses a master protocol to test multiple treatments, with aletekitug being one of them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Aletekitug (GSK1070806), an experimental biologic drug
- What this could lead to
- If successful, this could lead to a new treatment option that helps control ulcerative colitis symptoms and reduce disease activity.
- What could go wrong
- This is a very early, small trial focused on safety, not effectiveness. The drug may not work or could cause side effects, and more research will be needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Real-World study reveal the staying power of guselkumab?
- Can a new biologic calm the immune attack in ulcerative colitis?
- Can better detection of precancerous lesions in IBD prevent colorectal cancer?
- Dutch hospital data reveals hidden patterns in IBD treatment
- Kids' metabolism under the microscope: new study on IBD and energy burn
- New antibody cocktail aims to tame ulcerative colitis for good